Provided by Tiger Trade Technology Pte. Ltd.

WisdomTree BioRevolution Fund

23.48
-0.1524-0.64%
Volume:2K
Turnover:43.01K
Market Cap:4.70M
PE:- -
High:23.71
Open:23.71
Low:23.48
Close:23.63
52wk High:24.29
52wk Low:15.67
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.73
T/O Rate:0.91%
Dividend:0.77
Dividend Rate:3.28%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Twist Bioscience is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test

Simply Wall St.
·
Oct 01

Twist Bioscience price target raised to $212 from $107 at Guggenheim

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline

Dow Jones
·
Oct 01

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30